Chairman of the Board
“StemBioSys is uniquely positioned to provide break-through scientific advances for researchers, physicians and patients in the exciting field of regenerative medicine!.” – Catherine Burzik
Catherine Burzik is a seasoned senior executive and has successfully led a variety of life sciences companies.She injected new vitality into Kinetic Concepts, Inc., a leading medical device company, when she became President and CEO in 2006. She led a major global KCI expansion, including the $1.7 billion acquisition of LifeCell, a premier regenerative medicine company, and the sale of KCI for $6.1 billion (9 X EBITDA) in 2011.
Ms. Burzik previously had held senior executive positions with Applied Biosystems, Eastman Kodak and Johnson & Johnson.
She chairs the Dallas Federal Reserve Board’s San Antonio branch and the Canisius College Board of Trustees. Her extensive corporate and non-profit board experience also includes Bausch and Lomb, Cordis Corp., InHealth, Allscripts and the Keck Graduate School of Applied Life Sciences.
She founded and leads the Catherine and Francis Burzik Education Foundation, dedicated to the educational and artistic pursuits of qualified students.
Ms. Burzik holds an M.A. in math from the University of Buffalo and a B.A. in math and the classics from Canisius College.
“The combination of business acumen and strong science will continue to propel StemBioSys.” – Paul Castella
Paul Castella brings to StemBioSys an impressive track record of highly successful development and commercialization of life science startup companies.
In two years as co-founder, president and CFO, he led CardioSpectra to a $63-million acquisition by Volcano Corp. In addition, he has co-founded, managed and financed several other companies including Xenotope Diagnostics, which licensed its technology to Genzyme, and ViroXis, which has received funding from the State of Texas and is conducting an investigational new drug phase II study.
He co-founded Targeted Technology Fund I in 2009, immediately attracting a long list of life science business leaders to the fund’s focus on investment in promising startup enterprises.
The holder of 20 issued or pending patents, Dr. Castella serves as a director or advisor with numerous biotechnology and pharmaceutical companies. His skills in the evaluation, financing, licensing, formation and operation of life science companies continues to be in high demand.
Dr. Castella holds a Ph.D. in cell biology and genetics from Cornell University Medical College and an M.B.A. from the University of Texas.
“StemBioSys brings a new and creative approach to the challenge of stem cell growth.” – Jean Cheever
Jean Cheever acquired a broad and deep understanding of life sciences finance and management during her 16 years with Bristol-Myers Squibb, including her financial integration role in the merger of Bristol-Myers with Squibb Company.
She was responsible for an array of global initiatives that netted the company millions in cost reductions. Both a CPA and Certified Purchasing Manager, her career has included controller and audit leadership functions with a global accounting firm and a major industrial company.
Ms. Cheever’s creative side flourishes in her role as a theatre producer; credits include the Tony Award-nominated Dirty Rotten Scoundrels, and Off Broadway’s musical comedy, The Toxic Avenger. She also holds patents on two mobile applications for music and entertainment.
She serves on the board of Broadway Bank and is a founding member of the Director’s Council for the University of Texas at Austin Department of Theatre and Dance.
Ms. Cheever holds an M.B.A. from the University of Texas at Austin and a B.B.A. from Southern Methodist University.
“The work we have done to date is just the beginning. Now, we’re focused on taking what we have learned from the bench to practical application.” – Xiao-Dong Chen
Dr. Chen has spent his entire career studying the incredible potential of stem cells, going back to his University of Nebraska work to identify the embryonic origin of the hemato- poietic cells in the liver. His stem cell research continued through postdoctoral work at Yale University and later in his role as a senior fellow at the National Institutes of Health.
Advancing his research as a tenured professor at the University of Texas Health Science Center at San Antonio, Dr. Chen licensed his patents from the university as the foundation of his new company, StemBioSys. He serves as the company’s Chief Scientific Officer.
Based on his award-winning research, Dr. Chen has authored more than 40 peerreviewed articles related to stem cells, tissue engineering, cellular growth factors and differentiation.
Dr. Chen completed post-doctoral work at the Yale University School of Medicine. He holds a Ph.D. in developmental immunology and an M.S. in hematology from the University of Nebraska Medical Center, and a medical degree from the Shanghai Jiao-Tong University School of Medicine.
“StemBioSys is uniquely positioned as a key player in the emerging stem cell industry to make a real difference in patients lives.” – Ian Clements
Mr. Clements has over 25 years of experience in sales, marketing, medical affairs, project management and business development positions in large pharmaceutical companies, including 6 years at Pharmacia Upjohn as head of Global Oncology Marketing and 3 years as head of US Oncology Marketing for Novartis.
Previously, Ian served as head of Commercial Operations and Corporate Development for ILEX Oncology where he helped establish the new Business Development and Project Management systems. Ian also founded or co-founded several companies including C2XL Corporation, ViroXis Corporation and Santalis Pharmaceuticals.
Ian currently serves as CEO and President of ViroXis Corporation and Director and CBO for Santalis Pharmaceuticals.
In addition, Ian is a Managing Partner of Targeted technology Fund II, San Antonio’s first dedicated life science venture fund. Ian has a B.Sc. Hons degree in Genetics from Swansea University (Wales) and M.Sc. degree in Immunology from King’s College London, UK.
“The potential market for our platform technology is substantial. Dr. Chen’s approach to growing stem cells creates a whole new range of therapeutic opportunities.” – Steven A. Davis
Dr. Davis co-founded StemBioSys in 2010 along with Dr. Xiao-Dong Chen. Over the past 25 years, Dr. Davis has been involved with almost 200 clinical research studies for more than 60 companies including Abbott, Allergan, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Leo Pharma, Lilly, Novartis, Pfizer and TEVA Pharmaceuticals.
He serves as a clinical professor of dermatology at the University of Texas Health and Science Center at San Antonio and is a fellow of the American Academy of dermatology, the American Society for Laser Medicine and Surgery and the American Society for Dermatologic Surgery.
He also is the founder and medical director of the Dermatology and Laser Center of San Antonio. His syndicated daily radio feature, “Speaking of Health,” aired on the CBS Radio network for 34 years.
Dr. Davis is a founding member of BioMed SA, currently serves on its Executive Committee and co-chairs the San Antonio Biomedical Asset Initiative. Dr. Davis holds a B.A. in economics from Yale University and received his M.D. from the University of Texas Southwestern Medical School. He completed his residency at the University of California San Francisco Medical School.
“StemBioSys’s core technology offers a wide range of possibilities for the entire regenerative medicine field .” – John Feik
John Feik saw the untapped potential in a pharmaceutical manufacturing company, acquiring it in 1990 to form the foundation of DFB Pharmaceuticals. Over the next 22 years, he led DFB and its subsidiaries to more than $400 million in annual sales.
Feik guided the growth of DFB’s DPT Laboratories unit, which provides the pharmaceutical and biotech industry with drug development, manufacturing and packaging solutions. DPT clients include the world’s leading pharmaceutical, biotech and specialty pharmaceutical companies.
In addition he oversaw DFB’s Healthpoint Biotherapeutics, which was later acquired by Smith & Nephew, and other DFB operating units. Mr. Feik holds numerous civic leadership posts, including board positions at the Texas Research & Technology Foundation and the Texas Biomedical Research Institute.
He and Mrs. Feik founded the John & Rita Feik School of Pharmacy at the University of the Incarnate Word and underwrote the Rita & John Feik Distinguished Chair for Medicinal Chemistry at the University of Texas at San Antonio.
Mr. Feik holds a bachelor’s in finance from the University of Texas at Arlington.
“StemBioSys’s technology will be one of the key catalysts for changing regenerative Medicine in the years to come.” – Bob Hutchens, President & CEO
Bob is a retired Partner of Booz & Company in New York. Booz & Company is a billion dollar management consulting firm with over 70 offices worldwide. Prior to Booz & Company Bob was a partner with the Management consulting firm of A.T. Kearney in New York.
Bob has over 20 years of experience in management consulting. Most of his work has been with clients in the Life Sciences industry. His clients also included a number of major pharmaceutical companies as well as a range of medical device and supply companies.
Bob also worked extensively with Centers for Disease Control (CDC) in Atlanta to redesign the supply chain and financial processes for the agency’s $4 billion Vaccine For Children (VFC) program. Additionally, Bob worked with the President’s Emergency Program For Aids Relief (PEPFAR) as well as with the Global Fund.
Bob’s work with his clients addressed a range of topics including defining corporate strategies, developing market entry and launch strategies as well as working with these clients to improve the overall effectiveness of their organizations and operations. Bob holds a Bachelor of Business Administration from the Ross School of Business at The University of Michigan and he holds a Master of Business Administration from the Wharton School at the University of Pennsylvania.
“What I see at StemBioSys is a potential breakthrough in the way stem cells are produced for both research and therapeutic application.” – Robert S. Langer
Robert Langer brings an astounding record of scientific discovery, invention and business achievement to StemBioSys. He holds more than 1,050 issued and pending patents worldwide, and has licensed or sublicensed them to over 250 companies. Robert Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and, as one of the 11 Institute Professors, has received the highest honor that MIT can award to a faculty member.
Langer has served on some 30 scientific advisory boards or board of directors, including such companies as Wyeth, Warner-Lambert, Alkermes, and others. His success has been recognized by more than 220 major awards including the Charles Stark Draper Prize (considered the equivalent of the Nobel Prize for Engineers). He is also one of only 5 individuals ever elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors. News media ranging from Forbes and Time magazines to CNN have lauded Dr. Langer as one of the world’s most important scientific minds.
Dr. Langer earned a Sc.D. from the Massachusetts Institute of Technology and a B.S. from Cornell University, both in chemical engineering. He holds 22 honorary doctorates including honorary degrees from Harvard and Yale.